Entrada Therapeutics Inc (TRDA) Price & Analysis

Compare

102 Followers

TRDA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.93 - $21.79

Previous CloseN/A

Volume35.15K

Average Volume (3M)275.97K

Market Cap

$193.61M

Enterprise Value-$21.47M

Total Cash (Recent Filing)$354.01M

Total Debt (Recent Filing)$54.74M

Price to Earnings (P/E)7.4

Beta1.66

Next Earnings

Nov 11, 2025

EPS Estimate

-0.94

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.04

Shares Outstanding38,037,080

10 Day Avg. Volume333,673

30 Day Avg. Volume275,970

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.11

Enterprise Value/Revenue-0.27

Enterprise Value/Gross Profit-0.28

Enterprise Value/Ebitda0.23

Forecast

1Y Price Target

$18.50

Price Target Upside233.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentMultiple candidates advancing in clinical development. Since the beginning of this year, Entrada has advanced multiple clinical programs in people living with Duchenne muscular dystrophy (DMD) in the U.K., EU and U.S.

Financial StabilityThe company ended 2Q25 with $354M in cash, cash equivalents, and marketable securities, which we expect to be sufficient to fund operations into 2Q27.

Regulatory ProgressThe company has received authorization for a similar Phase I/II study for its exon 45 skipper in patients amenable for exon 45 skipping.

Bears Say

Revenue PerformanceEntrada Therapeutics recorded top-line revenue of ~$2M, missing our forecast of $8M.

Entrada Therapeutics Inc News

Entrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Paul Choi initiated coverage of Entrada Therapeutics (TRDA) with an Early-Stage Biotech designation, saying the...

3d ago

TRDA

Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital

Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $17 from $21 and keeps a...

1M ago

TRDA

Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Entrada Therapeutics Inc and keeping the price...

1M ago

TRDA

Entrada Therapeutics Reports Q2 2025 Financial Results

Entrada Therapeutics Inc ( ($TRDA) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

TRDA

Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics

William Blair analyst Myles Minter has reiterated their bullish stance on TRDA stock, giving a Buy rating today....

1M ago

TRDA

Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)

Reports Q2 revenue $1.95B, consensus $8.17M. “Now, more than ever, patients living with Duchenne muscular dystrophy need safer...

2M ago

TRDA

Entrada Therapeutics Holds Virtual Annual Stockholders Meeting

Entrada Therapeutics Inc ( ($TRDA) ) has issued an announcement. On June 11, 2025, Entrada Therapeutics, Inc. held...

3M ago

TRDA

Entrada Therapeutics Appoints New Board Member

An announcement from Entrada Therapeutics Inc ( ($TRDA) ) is now available. On May 30, 2025, Entrada Therapeutics...

4M ago

TRDA

Entrada Therapeutics appoints Radhakrishnan to board of directors

Entrada Therapeutics (TRDA) announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. Since August 2024,...

4M ago

TRDA

Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report)...

4M ago

TRDA

Entrada Therapeutics receives authorization from in EU to start ELEVATE-45-201

Entrada Therapeutics (TRDA) announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries...

4M ago

TRDA

Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Entrada Therapeutics (TRDA) to $21 from $23...

4M ago

TRDA

Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital

Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $21 from $23 and keeps a...

4M ago

TRDA

Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on TRDA stock, giving a Buy rating today....

4M ago

TRDA

TRDA FAQ

What was Entrada Therapeutics Inc’s price range in the past 12 months?

Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $21.79 in the past 12 months.

What is Entrada Therapeutics Inc’s market cap?

Entrada Therapeutics Inc’s market cap is $193.61M.

When is Entrada Therapeutics Inc’s upcoming earnings report date?

Entrada Therapeutics Inc’s upcoming earnings report date is Nov 11, 2025 which is in 52 days.

How were Entrada Therapeutics Inc’s earnings last quarter?

Entrada Therapeutics Inc released its earnings results on Aug 06, 2025. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.847 by -$0.193.

Is Entrada Therapeutics Inc overvalued?

According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Entrada Therapeutics Inc pay dividends?

Entrada Therapeutics Inc does not currently pay dividends.

What is Entrada Therapeutics Inc’s EPS estimate?

Entrada Therapeutics Inc’s EPS estimate is -0.94.

How many shares outstanding does Entrada Therapeutics Inc have?

Entrada Therapeutics Inc has 38,037,080 shares outstanding.

What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?

Entrada Therapeutics Inc reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.847. Following the earnings report the stock price went up 2.058%.

Which hedge fund is a major shareholder of Entrada Therapeutics Inc?

Currently, no hedge funds are holding shares in TRDA

Entrada Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-18.12%

Trailing 12-Months

Asset Growth

-22.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Entrada Therapeutics Inc

Entrada Therapeutics Inc (TRDA) is a biotechnology company focused on developing transformative therapies for patients with serious diseases, particularly in the field of genetic and rare disorders. The company utilizes its proprietary Transduction Enabled Therapeutics (TET) platform to create drug candidates that can effectively deliver therapeutic agents directly into cells, thereby addressing the underlying causes of diseases. Entrada operates primarily in the biopharmaceutical sector, with a commitment to advancing innovative treatments that leverage its unique technology for improved patient outcomes.

Entrada Therapeutics Inc (TRDA) Earnings & Revenues

Historic Earnings Reports

TRDA Stock 12 Month Forecast

Average Price Target

$18.50

▲(233.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.38,6.504615384615384,7.6292307692307695,8.753846153846155,9.87846153846154,11.003076923076925,12.127692307692309,13.252307692307692,14.376923076923077,15.501538461538463,16.626153846153848,17.750769230769233,18.87538461538462,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.38,6.389230769230769,7.398461538461539,8.407692307692308,9.416923076923077,10.426153846153847,11.435384615384617,12.444615384615386,13.453846153846154,14.463076923076922,15.472307692307695,16.481538461538463,17.49076923076923,{"y":18.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.38,6.273846153846154,7.167692307692308,8.061538461538461,8.955384615384617,9.849230769230768,10.743076923076924,11.636923076923079,12.53076923076923,13.424615384615386,14.318461538461538,15.212307692307693,16.10615384615385,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.25,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.47,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.96,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.32,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.44,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.94,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >